Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib Dose Ranging in Dry Eye Disease
NCT01135511Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2010
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of INN-04-01 in dry eye syndrome (DED) (5 arms), sponsored by Pfizer. Primary endpoint: Changes in Corneal Staining Scores for Study Eye From Baseline at Week 8. Started Jul 2010; status: completed.
02
Drugs
INN-04-01
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT01135511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01135511.